MedGen Life Sciences Secures Tens of Millions in Series A+ Funding to Build a Natural Bone Regeneration Materials Platform

VCBeat learned that recently, Shenzhen Medgen Life Sciences Co., Ltd. ("Medgen Life") announced it has completedYuanBio Venture Capital's Exclusive Investment of Tens of Millions of Yuan in Series A+ Financing.This round of financing is the company's second funding in nearly two months, with the total amount of the first two rounds of financing nearing 100 million yuan. This round of financing will further replenish the company’s working capital, to be used for the clinical advancement of Medgen Life Sciences' current medical aesthetics products, as well as the sales promotion of orthopedic innovative products after their market launch.Changhai Capital continues to serve as the exclusive financial advisor for the company's financing.

In the second half of 2024, with the outbreak of the Shanxi Aorui allogeneic bone incident, the severe shortage of high-quality bone materials was exposed to the public. Bone material companies such as Osteocore Medical and Zhenghai Bio gained a surge of limit-up trading in the secondary market. In November and December, two innovative products from Medgen Life Sciences' orthopedics division, artificial bone filler material and Platelet-Rich Plasma (PRP) preparation device, successively obtained registration certificates, precisely meeting the market's expectations for innovative products.

Currently, in the registration certificates for bone filler materials in China, the vast majority are made of bone cement, bioceramics, or synthetic hydroxyapatite. Although these products possess certain bionic structures and processing technologies, their clinical efficacy still cannot replace autologous bone, especially with significant differences in biological properties such as osteoinduction. Medgen Life Sciences has launched the first pre-filled injectable artificial bone in China based on natural hydroxyapatite material, which demonstrated excellent osteoinductive effects in preliminary experiments, comparable to autologous bone. In addition to its superior performance, the product design allows for direct filling without the need for on-site mixing, significantly reducing operation time.

Medgen Life Sciences Artificial Bone Product Image

Medgen Life Sciences' artificial bone induces twice the volume of bone tissue as its competitor at 6 weeks post-surgery, demonstrating a significant advantage.

Platelet-Rich Plasma (PRP) is a platelet concentrate obtained from autologous whole blood after centrifugation. It is rich in various bioactive substances such as growth factors, cytokines, and antimicrobial peptides, which can promote tissue cell proliferation and differentiation; facilitate cartilage and bone repair, accelerate healing; promote collagen and extracellular matrix synthesis, repair wounds, and stimulate regeneration. PRP therapy is currently widely used in orthopedics, sports medicine, medical aesthetics, and other fields. The plasma concentrator of Medgen Life Sciences features multiple unique patents, adopting a three-chamber independent sealed design with a fully closed separation process. Utilizing a two-step gradient centrifugation method, it achieves a perfect balance between preparation quality and efficiency, offering the most convenient adjustment and separation.

Medgen Life Sciences PRP Preparation Device Product

Similar to bone filling materials, hydroxyapatite, as a raw material for medical aesthetic regeneration injection fillers, also shows significant differences in effects between natural and synthetic materials. The porous structure of natural microspheres, with a larger porosity, provides stronger cell adhesion and more adsorption space, thereby achieving faster and greater collagen stimulation and regeneration."Better filling effect, more thorough metabolism". Multiple overseas studies have confirmed the advantages of natural-source hydroxyapatite over synthetic hydroxyapatite. Medgen Life Sciences is among the leading companies in China.The only enterprise adopting the natural hydroxyapatite technology routeCurrently, the company's multiple indications for medical aesthetics injection fillers are proceeding intensively and smoothly in clinical trials.

Currently, Medgen Life Sciences is methodically expanding its layout in research and development, marketing, and sales. In the future, the company will maintain a balanced and rapid development in both serious medicine and consumer healthcare sectors, striving to buildA multi-field, multi-product structure natural ingredient regeneration and repair platform enterprise。

Talking about this round of financing,Founder and CEO of Medgen Life Sciences, Deng SilingExpressed: Thanks to YuanBio Venture Capital for recognizing the company. The company has achieved nearly 100 million yuan in financing in just two months and has made substantial progress in multiple pipelines, including orthopedics and medical aesthetics. The rapid market launch of the PRP concentrator and bone filler products demonstrates the strong capabilities of Medgen's R&D, clinical, and registration teams, as well as the value of Medgen’s commitment to its natural raw material technology platform. Through the expansion of multiple product lines and continuous market education in the future, Medgen hopes to become not only a company focused on medical aesthetics or orthopedic materials but also a leader in promoting the concept of natural bone repair and regeneration materials across the industry.

YuanBio Venture Capital Partner Gu LeiminHydroxyapatite is widely used in the medical field, and natural-source hydroxyapatite has unique advantages in tissue repair, filling, and induced regeneration. Medgen Life Sciences focuses on new regenerative materials, emphasizing the sourcing and processing of natural raw materials, and has made encouraging progress in both medical aesthetics and serious medical fields.Liu Xiao, Managing Director of YuanBio Venture CapitalRemark: In recent years, the market education for regenerative injectables has been completed. Both institutions and beauty seekers are looking forward to the launch of compliant new products. We have great confidence in Mr. Deng's team for their resilience and execution capabilities. Medgen Life Sciences' product pipelines, such as natural porous hydroxyapatite and collagen, have enriched consumer choices. We anticipate that Medgen will provide safer and more effective anti-aging solutions in the future.

Wang Keshu, Partner of Changhai CapitalIt is a great pleasure to have the opportunity to continue our cooperation with Medgen Life Sciences and swiftly complete an additional round of financing amidst the capital winter. This fully demonstrates that in the highly competitive bone and medical aesthetics materials market, platform enterprises with truly unique concepts and differentiated value will always be favored by opportunities. Medgen Life Sciences is one of the few platform enterprises in the entire industry that possesses a high-level technical barrier, product philosophy, and management capabilities. We also welcome various orthopedic platform companies and channel-oriented enterprises to inquire about cooperation with Medgen Life Sciences.

YuanBio Venture Capital is an investment institution focusing on early-stage and growth-stage healthcare sectors, based in Suzhou bioBAY with a global reach. It has successfully invested in over 190 outstanding companies in the life sciences sector, covering four major areas: novel drug development, medical devices, in vitro diagnostics and precision medicine, as well as healthcare services, achieving substantial investment returns. Among these, 19 companies have gone public on capital markets such as the Hong Kong Stock Exchange and the STAR Market. YuanBio Venture Capital has been repeatedly recognized as one of the Top 10 venture capital funds in China's healthcare sector and one of the most active healthcare investment institutions in China. With a team of experienced professional investors and a world-class scientific advisory board, YuanBio Venture Capital possesses extensive entrepreneurial, venture capital, and corporate operational experience in the biopharmaceutical industry. Leveraging professionalism, dedication, and abundant industry resources, we are committed to becoming one of the most successful healthcare and pharmaceutical venture capital funds in China.

Changhai Capital is a financial advisor focused on the healthcare and advanced manufacturing sectors, providing enterprises with in-depth, customized financing strategies and services. The team has extensive industry experience in the fields of life sciences, medical devices, diagnostics, and advanced manufacturing. They have led and participated in the financing of several high-profile companies, assisting enterprises in rapid growth and maximizing their value.